Pure Global AI
NCT06349252Recruiting

Survival Validation and Gene Mutations of N Descriptors in the Ninth Edition of the TNM Classification for Lung Cancer

Fudan UniversityClinicalTrials.govprocedure
Verified
Study focus
Disease/Condition
Non-small Cell Lung Cancer
Drug/Device/Intervention
Radical resection
Study type
Observational
Intervention type
procedure
Sponsor & location
Primary sponsor
Fudan University
Location
Shanghai, China
Timeline & enrollment
Phase
N/A
Start date
Jan 01, 2021
End date
Jan 01, 2025
Enrollment
1263 participants
Primary outcome

Overall Survival

Summary

The International Association for the Study of Lung Cancer Staging Committee recently
 unveiled the ninth edition of TNM staging system for lung cancer. This study aims to explore
 survival outcomes, stage grouping, and gene mutations in N descriptors of this new
 classification system.

ICD-10 classifications
Secondary malignant neoplasm of lungMalignant neoplasm: Lower lobe, bronchus or lungMalignant neoplasm: Middle lobe, bronchus or lungMalignant neoplasm: Bronchus or lung, unspecifiedMalignant neoplasm of bronchus and lung
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06349252
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06349252 through Pure Global AI's free database. This phase not specified trial is sponsored by Fudan University and is currently Recruiting. The study focuses on Non-small Cell Lung Cancer. Target enrollment is 1263 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.